Qualigen Therapeutics Total Stockholder Equity Over Time
| QLGN Stock | USD 3.76 0.14 3.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Qualigen Therapeutics Performance and Qualigen Therapeutics Correlation. Qualigen |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.5 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Stockholder Equity Analysis
Compare Qualigen Therapeutics and related stocks such as ZyVersa Therapeutics, Immix Biopharma, and Phio Pharmaceuticals Corp Total Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZVSA | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (8.6 M) | (12.5 M) | 100 M | 11.1 M | 10.5 M |
| IMMX | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (4.7 M) | 18 M | 13.2 M | 16.4 M | 8.6 M |
| PHIO | (587 K) | (587 K) | (5.8 M) | 4.9 M | 2.7 M | 8.9 M | 10.9 M | 1.8 M | 13.6 M | 5.7 M | 13 M | 21.9 M | 10.8 M | 7.7 M | 8.1 M |
| ATNF | 21.9 K | 21.9 K | 21.9 K | 21.9 K | 21.9 K | 21.9 K | 21.9 K | 5 M | 5 M | 38.6 M | 30.3 M | 39.3 M | 11.3 M | (127.7 K) | (121.3 K) |
| ENTX | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.2 M) | (31.6 M) | 10.1 M | 11.9 M | 6.7 M | 22.6 M | 11.8 M | 10.4 M | 10.9 M |
| ANEB | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | (171.1 K) | 21.4 M | 15.1 M | 10.6 M | 3.8 M | 3.6 M |
| INDP | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | (237.7 K) | 35.9 M | 24.6 M | 12.1 M | 18.5 M |
| ASMB | (9.5 M) | 34.5 M | 17.8 M | 24.5 M | 58.6 M | 118.7 M | 79.9 M | 113.1 M | 210.7 M | 273.2 M | 240.6 M | 168.9 M | 82.7 M | 41.1 M | 39 M |
| VRAX | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (596.2 K) | (974.6 K) | 9.1 M | 5.4 M | 5.6 M |
| REVB | 168.8 M | 168.8 M | 168.8 M | 168.8 M | 168.8 M | 168.8 M | 168.8 M | 188.3 M | 264.9 M | (3.6 K) | 3.4 M | (99.5 K) | 1.1 M | 6.6 M | 6.3 M |
| KPRX | (41.2 M) | (41.2 M) | (41.2 M) | (44.8 M) | (46.8 M) | 6.1 M | (329.4 K) | (1.9 M) | 8.9 M | 6.6 M | 7 M | 9.2 M | 11.4 M | 6.1 M | 6.4 M |
| SLRX | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | 92.2 M | 59.3 M | 29.1 M | 9.3 M | 10.6 M | 22.2 M | 38.7 M | 10.4 M | 5.3 M | 5 M |
| NTRB | (11.5 K) | (11.5 K) | (11.5 K) | (11.5 K) | (11.5 K) | (11.5 K) | 23.1 K | 121.5 K | 2.4 M | 175.4 K | 7.1 M | 11.9 M | 8.6 M | 6.4 M | 4.5 M |
| ALRN | (82 M) | (82 M) | (82 M) | (82 M) | (82 M) | (94.3 M) | (111.8 M) | 47.8 M | 19.6 M | 16 M | 12.2 M | 43.9 M | 18.6 M | 6.9 M | 7.2 M |
Qualigen Therapeutics and related stocks such as ZyVersa Therapeutics, Immix Biopharma, and Phio Pharmaceuticals Corp Total Stockholder Equity description
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.My Equities
My Current Equities and Potential Positions
| Qualigen Therapeutics | QLGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.76
Check out Qualigen Therapeutics Performance and Qualigen Therapeutics Correlation. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Qualigen Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.